The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the announcement of encouraging trial results. With the stock currently trading at $0.

Notable insider trades include STEINER MITCHELL SHUSTER, President and CEO at Veru Inc (VERU), who sold 84021 shares on May 15 ’24, at $1.5 each, totaling $0.13 million.

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Barclays PLC lifted its position in shares of Veru Inc. (NASDAQ:VERU – Free Report) by 309.2% during the 3rd quarter, ...